<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00747799</url>
  </required_header>
  <id_info>
    <org_study_id>BAY43-9006-2008003</org_study_id>
    <nct_id>NCT00747799</nct_id>
  </id_info>
  <brief_title>Study of Combination of Sorafenib With Cisplatin and 5-fluorouracil as First-line Treatment of Recurrence After Radiotherapy Patients Who Failed With Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)</brief_title>
  <official_title>Phase II Study of Combination of Sorafenib With Cisplatin and 5-fluorouracil as First-line Treatment of Recurrence After Radiotherapy Patients Who Are Failure of Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <brief_summary>
    <textblock>
      This study is a phase II clinical study. Recurrence after radiotherapy patients who are&#xD;
      failure of radiotherapy in recurrent or metastatic nasopharyngeal carcinoma (NPC) were&#xD;
      treated by cisplatin and 5-fluorouracil with Sorafenib as first-line treatment. The objective&#xD;
      response(complete response (CR) + partial response (PR)), Disease Control Rate , safety&#xD;
      profile, tolerability will be evaluated according to World Health Organization (WHO)&#xD;
      criteria.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (CR+PR)</measure>
    <time_frame>January 2009 to May 2011</time_frame>
    <description>In the ITT analysis(n=54), the ORR reached 77.8%: one patient (1.9%) experienced CR; 41 (75.9%), PR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>January 2009 to May 2011</time_frame>
    <description>The disease control rate (DCR) was 90.8%.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Nasopharyngeal Neoplasms</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sorafenib with Cisplatin and 5-fluorouracil as first-line treatment of recurrence after radiotherapy patients who failed with radiotherapy in recurrent or metastatic nasopharyngeal carcinoma (NPC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib plus Cisplatin and 5-fluorouracil</intervention_name>
    <description>Sorafenib with Cisplatin and 5-fluorouracil as first-line treatment of recurrence after radiotherapy patients who failed with radiotherapy in recurrent or metastatic nasopharyngeal carcinoma (NPC)&#xD;
Sorafenib 400 mg bid per daily . Every 21-day cycles.&#xD;
Cisplatin 80 mg/m2 day d1, every 21 days cycle.&#xD;
5-fluorouracil 1000 mg/m2 day CIV 4days, repeat 21-day cycles</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt; 18 years&#xD;
&#xD;
          2. ECOG Performance Status of 0 or 1&#xD;
&#xD;
          3. Life expectancy of at least 12 weeks&#xD;
&#xD;
          4. Pathologically confirmed nasopharyngeal carcinoma&#xD;
&#xD;
          5. Experience of treatment failure with radiotherapy for recurrent or metastatic NPC&#xD;
&#xD;
          6. More than 3 weeks must have elapsed since previous radiotherapy&#xD;
&#xD;
          7. Biomarkers measuring including pERK, EGFR of original diagnostic paraffin-embedded&#xD;
             tumor samples; VEGF of pre-dose and post-dose plasma samples.&#xD;
&#xD;
          8. Subjects with at least one (for RECIST) measurable lesion (Tumor lesions that are&#xD;
             situated in a previously irradiated area could not be considered measurable)&#xD;
&#xD;
          9. Adequate bone marrow, liver and renal functions as assessed by the following&#xD;
             laboratory requirements to be conducted within 7 days prior to screening:&#xD;
&#xD;
               -  Hemoglobin &gt; 9.0 g/dl&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &gt; 1,500/mm3&#xD;
&#xD;
               -  Platelet count &gt; 100,000/Î¼l&#xD;
&#xD;
               -  Total bilirubin &lt; 1.5 times the upper limit of normal&#xD;
&#xD;
               -  ALT and AST &lt; 2.5 x upper limit of normal (&lt; 5 x upper limit of normal for&#xD;
                  patients with liver involvement of their cancer), Alkaline phosphatase &lt; 4 x ULN&#xD;
                  ,PT-INR/PTT &lt; 1.5 x upper limit of normal, Serum creatinine &lt; 1.5 x upper limit&#xD;
                  of normal&#xD;
&#xD;
         10. Signed and dated informed consent before the start of specific protocol procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of cardiac disease: congestive heart failure &gt; NYHA class 2; active CAD (MI&#xD;
             more than 6 mo prior to study entry is allowed); cardiac arrhythmias requiring&#xD;
             anti-arrhythmic therapy (beta blockers or digoxin are permitted) or uncontrolled&#xD;
             hypertension.&#xD;
&#xD;
          2. History of HIV infection&#xD;
&#xD;
          3. Active clinically serious infections (&gt; grade 2 NCI-CTC version 3.0)&#xD;
&#xD;
          4. Symptomatic metastatic brain or meningeal tumors (unless the patient is &gt; 6 months&#xD;
             from definitive therapy, has a negative imaging study within 4 weeks of study entry&#xD;
             and is clinically stable with respect to the tumor at the time of study entry)&#xD;
&#xD;
          5. History of organ allograft the organ allograft may be allowed as protocol specific.&#xD;
&#xD;
          6. Patients with evidence or history of bleeding diatheses&#xD;
&#xD;
          7. Previous or concurrent cancer that is distinct in primary site or histology from the&#xD;
             cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal&#xD;
             cell carcinoma, superficial bladder tumors [Ta, Tis &amp; T1] or any cancer curatively&#xD;
             treated &gt; 3 years prior to study entry.&#xD;
&#xD;
          8. Pregnant or breast-feeding patients. Women of childbearing potential must have a&#xD;
             negative pregnancy test performed within 7 days of the start of treatment. Both men&#xD;
             and women enrolled in this trial must use adequate barrier birth control measures&#xD;
             during the course of the trial and two weeks after the completion of trial.&#xD;
&#xD;
          9. Patients unable to swallow oral medications&#xD;
&#xD;
         10. Prior use of farnesyl transferase, Raf kinase, or MEK inhibitors&#xD;
&#xD;
         11. Investigational drug therapy outside of this trial during or within 4 weeks of study&#xD;
             entry&#xD;
&#xD;
         12. Prior exposure to the study drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Center of Sun-Yat Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <study_first_submitted>September 4, 2008</study_first_submitted>
  <study_first_submitted_qc>September 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2008</study_first_posted>
  <last_update_submitted>December 8, 2013</last_update_submitted>
  <last_update_submitted_qc>December 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Li Zhang</investigator_full_name>
    <investigator_title>Profressor</investigator_title>
  </responsible_party>
  <keyword>recurrent or metastatic Nasopharyngeal Neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

